Reading a Microcurrent Study: How to Tell Marketing Stats from Real Clinical Data

About the Authors

Bertica M. Rubio, M.D.

Bertica M. Rubio, M.D.

Director Médico, Clínica de Medicina Regenerativa y Antienvejecimiento | Médico Certificado por la Junta | Escuela de Medicina de Dartmouth

La Dra. Bertica M. Rubio es una médica certificada y Directora Médica de la Clínica de Medicina Regenerativa y Antienvejecimiento en Redlands, California. Obtuvo su licenciatura en Ciencias en la Universidad Loyola Marymount y su título de Doctora en Medicina en la Escuela de Medicina de Dartmouth (Geisel School of Medicine). Completó su residencia en pediatría en el Centro Médico UC Irvine.

Con décadas de experiencia clínica, la Dra. Rubio se especializa en medicina para el manejo de la edad, medicina regenerativa, cicatrización de heridas y terapias con factores de crecimiento. Su práctica integra la ciencia médica basada en evidencia con tratamientos estéticos y regenerativos avanzados, ayudando a los pacientes a alcanzar una salud óptima y vitalidad juvenil.

La Dra. Rubio siente pasión por educar a los pacientes sobre la ciencia detrás del cuidado de la piel, el rejuvenecimiento facial y las tecnologías no invasivas como EMS (Estimulación Eléctrica Muscular) para el tonificado facial. Sus artículos para PureLift LAB combinan un conocimiento médico riguroso con orientación práctica para lograr resultados reales y duraderos.

Andrew Conrad Barile, Fisioterapeuta, Doctor en Terapia Física

Andrew Conrad Barile, Fisioterapeuta, Doctor en Terapia Física

Doctorado en Terapia Física (DPT), Fisioterapeuta Licenciado (PT)

El Dr. Andrew Conrad Barile es Doctor en Terapia Física y CEO y Fundador de Xtreem Pulse LLC. Obtuvo su Doctorado en Terapia Física en Daemen College y aporta más de dos décadas de experiencia clínica y empresarial en terapia física pediátrica, terapia craneosacral e innovación en dispositivos médicos. Su profundo conocimiento de la anatomía humana, la fisiología muscular y la tecnología terapéutica ofrece un enfoque invaluable respaldado por la ciencia para la rejuvenecimiento facial y soluciones antienvejecimiento.

Daniel Grinberg, MD, FACS

Daniel Grinberg, MD, FACS

Otorrinolaringólogo y cirujano de cabeza y cuello certificado | Miembro, Colegio Americano de Cirujanos | Profesor clínico asistente, Escuela de Medicina Mount Sinai

Daniel Grinberg, MD, FACS, es un otorrinolaringólogo certificado por la junta y cirujano de cabeza y cuello en ENT and Allergy Associates en West Nyack, NY. Obtuvo su título de médico en la Facultad de Médicos y Cirujanos de la Universidad de Columbia, completó su residencia en Otorrinolaringología en el Centro Médico de la Universidad de Nueva York y es profesor clínico asistente en la Escuela de Medicina Mount Sinai. Es miembro de la American College of Surgeons y de la American Academy of Otolaryngology.

La perspectiva quirúrgica de cabeza y cuello del Dr. Grinberg ofrece a los lectores de PureLift LAB una visión clínica más amplia, conectando la práctica de EMS en casa con la anatomía médica subyacente con el mismo rigor científico que aplicamos a cada especificación del dispositivo.

Prof. Dr. med. Ivo Buschmann

Prof. Dr. med. Ivo Buschmann

Cátedra de Angiología, Hochschule Médica de Brandeburgo | Director de Clínica, Clínica Universitaria de Angiología, Hospital Universitario de Brandeburgo | Ex Consultor Senior, Charité Universitätsmedizin Berlín

El Prof. Dr. med. Ivo Buschmann es Catedrático de Angiología en la Medizinische Hochschule Brandenburg Theodor Fontane (MHB) y Director Clínico de la Clínica Universitaria de Angiología en el Hospital Universitario de Brandeburgo. Completó su formación médica en la Universidad de Hamburgo, fue becario de la Sociedad Max-Planck en el Instituto Max-Planck de Investigación Cardiaca y Pulmonar, y ocupó cargos de consultor senior en la Charité Universitätsmedizin Berlin Campus Virchow antes de ser nombrado Catedrático en la MHB en 2016.

El Prof. Buschmann es una de las principales autoridades europeas en arteriogénesis — el crecimiento y remodelación de los vasos sanguíneos impulsados por el flujo — con más de 150 publicaciones revisadas por pares y varias patentes en EE. UU. y la UE sobre dispositivos que estimulan el crecimiento de vasos colaterales mediante terapia controlada de tasa de cizalladura. Su investigación conecta la estimulación mecánica y eléctrica con la adaptación vascular, la microcirculación y la perfusión tisular.

Las contribuciones del Prof. Buschmann aportan a los lectores de PureLift LAB una perspectiva de biología vascular que complementa nuestra autoría clínica, de fisioterapia y de anatomía quirúrgica existente — explicando cómo la estimulación EMS activa no solo los músculos faciales sino también la microcirculación que los abastece, y por qué la administración inteligente es tan importante a nivel del flujo sanguíneo como en la contracción muscular.

The at-home facial device category is full of impressive-sounding numbers. Four hundred percent ATP boost. Twelve hundred microamps of advanced microcurrent. Eighteen point six percent muscle thickness increase. Each of these has appeared in marketing materials at some point, and each carries a specific meaning that the marketing context does not always make clear. The user trying to evaluate a device based on its claimed evidence ends up navigating between numbers that look comparable but are not, and between claims that look scientific but rest on different foundations.

This article walks through how to read a microcurrent or EMS study with enough rigor to separate the marketing number from the clinical reality. It is written from the perspective of someone trying to make an informed buying decision, not from the perspective of someone trying to publish in a peer-reviewed journal, so the language is intentionally accessible.

The first question to ask

The first question to ask about any claimed result is what was actually measured. A claim like "four hundred percent ATP boost" sounds impressive, but the user evaluating the claim needs to know whether the measurement happened in cells in a petri dish, in tissue from animals, in human skin biopsies, or in any kind of clinical study with actual users on actual faces. The answer matters because the relevance of each measurement to the real-world cosmetic outcome is very different.

Cellular studies, where researchers culture cells in a lab and apply electrical stimulation, can produce dramatic numbers. The cells respond, the markers change, and the results look striking. The relevance to what happens when a device touches a human face for ten minutes a day is unclear. Cellular results provide useful evidence that an effect is possible in principle, but they are several steps removed from clinical relevance.

Animal studies bring the measurement closer to whole organisms but still have substantial translation gaps. Most cosmetic device claims that cite animal research do so because human research at the same level of detail does not exist for the device.

Clinical studies on actual humans, with documented protocols, blinded assessment where possible, and reasonable sample sizes, are the most directly relevant evidence. These are also the rarest in the device category because they are expensive and time-consuming to run.

The second question, what was the comparison

A claim of improvement is meaningful only against a baseline or a control. The second question to ask is what the result was compared to. Improvement compared to no treatment is the weakest possible comparison, because the natural variability in skin appearance from day to day can produce apparent change without any device involvement. Improvement compared to a sham device (a placebo device that looks similar but does not deliver the intended signal) is more meaningful, because it controls for the act of using a device at all. Improvement compared to another active treatment is the most rigorous, because it tells you whether the device performs better than alternatives in the user's situation.

Most cosmetic device studies use the first or second comparison type. Direct head-to-head comparisons with competing devices are rare, both because they are expensive to run and because the results would carry obvious marketing implications.

When a claim says "improvement over baseline," the user reading the claim should understand that this is the weakest of the three comparison types. The result might be real, but the comparison does not address whether the improvement is bigger than what would have happened with any other input, including doing nothing while paying attention to the face.

The third question, how many people

Sample size matters more than most marketing materials acknowledge. A study with eight users showing dramatic improvement is provocative but not conclusive. A study with a hundred users showing modest improvement is much more reliable evidence that the effect is real. The variability between individuals is large enough that small studies regularly produce results that do not replicate in larger studies.

The reasonable mental shortcut is to weight study results by approximate sample size. Studies with under twenty users in each group should be treated as hypothesis-generating rather than conclusive. Studies with fifty to a hundred users in each group are getting closer to conclusive. Studies with several hundred users provide more robust evidence.

The cosmetic device literature contains very few studies in the larger-sample range. Most published evidence is in the smaller-sample range. This is not a fatal flaw of the field, but it does mean that confident claims based on small studies should be treated with appropriate caution.

The fourth question, who funded the study

Industry-funded research is not automatically bad research, but the funding source matters. A study funded by the device manufacturer is more likely to produce results favorable to the device than an independently funded study on the same question. This is well-documented across many fields of medicine and consumer products research. The bias is rarely fraudulent in any direct sense; it operates through study design choices, what gets measured, how outcomes are reported, and what gets published versus what stays in the file drawer.

The strongest evidence base for any device category is independent research, ideally from multiple research groups, published in peer-reviewed journals, with results that agree across studies. The cosmetic device category has relatively little of this kind of evidence because the funding model has historically pushed research toward sponsor-funded studies. The user reading any claim should check whether the cited research is industry-funded or independent, and weight the confidence accordingly.

The fifth question, what is the effect size in practical terms

A statistically significant result is not the same as a practically meaningful result. Studies with enough users can detect very small effects as statistically significant, which sounds impressive in marketing materials but may translate to changes the user cannot see in the mirror.

The most useful question to ask about any reported result is what the effect size actually means in the real world. An eighteen point six percent increase in muscle thickness, for example (a number that has appeared in our own references from Kavanagh and colleagues in 2012), translates to visible changes in the resting position of the affected muscles across consistent twelve-week use. That is a practically meaningful effect size, demonstrated in a study with appropriate methodology.

Numbers like four hundred percent or twelve hundred microamps, on the other hand, often turn out to be measurements of inputs or intermediate markers rather than measurements of cosmetic outcomes. They sound dramatic but may not translate to visible change.

Putting it together

A practical mental checklist for reading any device claim looks like this. What was measured. What was the comparison. How many people were studied. Who funded the study. What does the effect size mean for what you would actually see in the mirror. Five questions, each of which takes a minute to answer if the claim is well-supported and takes much longer if it is not. If the answers to any of the five are unsatisfying, the appropriate response is to weight the claim accordingly rather than rejecting it outright.

The PureLift evidence base, available on our references hub and embedded throughout this content cluster, is built on PubMed-verified studies in the modulated EMS and facial NMES literature. The two most-cited pieces are Kavanagh and colleagues in 2012, who documented an eighteen point six percent mean increase in zygomaticus major muscle thickness across twelve weeks of facial NMES, and Omatsu and colleagues in 2024, who documented improvements in cheek volume, jawline angle, submental volume, and skin elasticity across eight weeks of split-face facial NMES. Both are clinical studies in humans, with appropriate methodology and reasonable sample sizes for the cosmetic device category.

The bottom line

Marketing numbers in the at-home facial device category vary widely in their underlying rigor. Some claims rest on clinical research in actual humans with appropriate methodology. Some rest on cellular studies that may or may not translate to visible change. Some rest on intermediate measurements that sound impressive but do not address the cosmetic outcome the user actually cares about. The five-question checklist (what was measured, what was the comparison, how many people, who funded the study, what does the effect size mean) gives the user a practical way to evaluate any device claim with appropriate rigor. Used consistently, this kind of reading separates the marketing number from the clinical reality and supports more confident buying decisions.

For more on the PureLift evidence base, see our references hub. For the modulation specifics, see Modulated vs. Fixed Frequency EMS.

Regresar al blog